摘要
新型冠状病毒肺炎(COVID-19)是由2019-新型冠状病毒(2019-nCoV)引起的新发急性呼吸道传染病,已成为全球性重大公共卫生事件,严重威胁人类健康。到目前为止,针对2019-nCoV的特效抗病毒药物和安全有效的疫苗仍在研发中,因此迫切需要为COVID-19的治疗寻找替代策略。感染性疾病康复者的恢复期血浆(Convalescent plasma,CP),特别是含有高滴度中和抗体的CP,被应用于治疗严重急性呼吸综合征(SARS)和中东呼吸综合征(MERS)等重大感染性疾病,取得令人满意的临床治疗效果。因此,COVID-19康复者CP是治疗重症和危重症2019-nCoV感染者的一项有意义的举措,但其潜在的风险仍待研究。本文就COVID-19康复者CP临床治疗的机制、采集要点、临床应用情况及潜在的益处和风险进行综述,为精准应用COVID-19康复者CP的临床治疗提供科学参考。
COVID-19 is an acute respiratory infectious disease caused by 2019-nCoV,which has become a major global public health event and a serious threat to human health.So far,specific antiviral drugs,safe and effective vaccines for 2019-nCoV are still under development,so there is an urgent need to find alternative strategies for the treatment of COVID-19.Convalescent plasma(CP)contains high titer neutralizing antibodies from patients recovering from infectious diseases,which has been used in the treatment of major infectious diseases such as severe acute respiratory syndrome(SARS)and Middle East respiratory syndrome(MERS),and achieved satisfactory clinical results.Therefore,CP from COVID-19 patient is a meaningful choice for the treatment of severe or life-threatening COVID-19 patients,but its potential risks need to be studied.This review focuses on the clinical mechanism,collection points,clinical application and potential benefits and risks of clinical treatment of CP from COVID-19 patients,which will provide reference for the clinical application of CP from COVID-19 patients.
作者
李阿中
蒋琦
崔大伟
Li Azhong;Jiang Qi;Cui Dawei(Department of Blood Preparation,Zhejiang Provincial Blood Center,Hangzhou 310053,China;Department of Blood Transfusion,Shaoxing People’s Hospital,Shaoxing Hospital of Zhejiang University,Shaoxing 312000,China;Department of Blood Transfusion,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China)
出处
《中华临床感染病杂志》
CAS
CSCD
2021年第1期24-28,65,共6页
Chinese Journal of Clinical Infectious Diseases
基金
国家自然科学基金(81871709)。
